Ethanol in alcoholic beverages is a causative agent for colorectal cancer. Colorectal cancer is a biologically heterogeneous disease, and molecular subtypes defined by the presence of somatic mutations in BRAF and KRAS are known to exist. We examined associations between lifetime alcohol intake and molecular and anatomic subtypes of colorectal cancer. We calculated usual alcohol intake for 10-year periods from age 20 using recalled frequency and quantity of beverage-specific consumption for 38,149 participants aged 40-69 years from the Melbourne Collaborative Cohort Study. Cox regression was performed to derive hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between lifetime alcohol intake and colorectal cancer risk. Heterogeneity in the HRs across subtypes of colorectal cancer was assessed. A positive dose-dependent association between lifetime alcohol intake and overall colorectal cancer risk (mean follow-up 5 14.6 years; n 5 596 colon and n 5 326 rectal cancer) was observed (HR 5 1.08, 95% CI: 1.04-1.12 per 10 g/day increment). The risk was greater for rectal than colon cancer (p homogeneity 5 0.02). Alcohol intake was associated with increased risks of KRAS1 (HR 5 1.07, 95% CI: 1.00-1.15) and BRAF2/KRAS2 (HR 5 1.05, 95% CI: 1.00-1.11) but not BRAF1 tumors (HR 5 0.89, 95% CI: 0.78-1.01; p homogeneity 5 0.01). Alcohol intake is associated with an increased risk of KRAS1 and BRAF2/KRAS-tumors originating via specific molecular pathways including the traditional adenoma-carcinoma pathway but not with BRAF1 tumors originating via the serrated pathway. Therefore, limiting alcohol intake from a young age might reduce colorectal cancer originating via the traditional adenoma-carcinoma pathway.
Ethanol in alcoholic beverages is a carcinogen 1 that increases the risk of colorectal cancer. 2 Although colorectal cancer is generally referred to as a single, broad disease entity, it is a heterogeneous group of diseases in terms of molecular pathology and prognosis. 3, 4 A number of molecularly defined subtypes of colorectal cancer have been described related to the presence of key somatic events including microsatellite instability (MSI), the CpG island methylator phenotype (CIMP), chromosomal instability and somatic mutations in the oncogenes BRAF, KRAS and PIK3CA. 5 For instance, colorectal cancers with BRAF mutation are considered a distinct group 3, 6 while a combination of features sets KRAS-mutated colorectal cancers apart from tumors harboring neither BRAF nor KRAS mutation. 7 Smoking has been consistently shown to have differences in associations with the risk of specific molecular subtypes of colorectal cancer. [8] [9] [10] Findings for alcohol thus far have been inconsistent: increased risks of MSI-low 8 and MSI-high 11, 12 colorectal cancer as well as an absence of a difference in association with MSI 13, 14 or BRAF and CIMP 15, 16 subtypes have been reported; associations for KRAS or combined BRAF/ KRAS subtypes are not available. Similarly, uncertainty remains whether alcohol consumption poses a greater risk for rectal cancer over colon cancer: mechanistically, this is plausible considering that the rectal mucosa is exposed to a greater carcinogenic effect of acetaldehyde due to its higher concentration. 17 In this study, we examined the associations between lifetime alcohol intake and colorectal cancer risk, overall and by subtypes defined by BRAF V600E and KRAS codons 12 and 13 somatic mutation status, and anatomic location (colon versus rectal), using data from the Melbourne Collaborative Cohort Study (MCCS).
Material and Methods

Study population
The MCCS is a prospective cohort study of 41,514 people (99.2% aged 40-69 years; 58.9% women) recruited during 1990-94 from Melbourne. 18 Participants were recruited through the electoral rolls (registration to vote is compulsory for adults in Australia), advertisements and community announcements in local media (such as television, radio, newspapers). Participants attended clinics where demographic, anthropometric, lifestyle and dietary information were collected and anthropometric measurements were performed. Participants aged <40 (n 5 194) and 701 years (n 5 131) at baseline, with a confirmed cancer diagnosis before baseline (n 5 1,467), missing alcohol consumption data for any age period (n 5 22), reporting implausibly high alcohol intake (n 5 616) or extreme values of total energy intake (<1st percentile and >99th percentile) (n 5 779), and missing data on any of the covariates modeled (n 5 156) were excluded, leaving 38,149 (91.9% of all participants) eligible for this analysis (Fig. 1 ). The study protocol was approved by the Cancer Council Victoria's Human Research Ethics Committee. Participants gave written informed consent to participate and for investigators to obtain access to their medical records.
Baseline data collection
A structured interview schedule was used at baseline to obtain information on potential risk factors including age, sex, country of birth, education, smoking habits, physical activity and previous medical conditions. A 121-item food frequency questionnaire was used to collect dietary information. 19 Waist circumference was measured using a standard protocol. Baseline residential addresses were used to classify participants into quintiles of an area-based measure of socioeconomic status. 20 
Assessment of alcohol consumption
Participants were asked at baseline if they had ever drunk at least 12 alcoholic drinks in a year. Those who had ("non-lifetime abstainers") were then asked about their usual frequency of consumption and usual quantity consumed per drinking occasion for beer, wine and spirits separately during 10-year age periods commencing at age 20, up to the decade of their age at baseline attendance. Usual intake within each age period in grams per day for each beverage type was calculated by multiplying intake frequency by quantity and standard amount of alcohol per container using Australian food composition tables. 21 The alcohol intake for each age period in grams per day was calculated as the sum of intake from the three beverage types. The baseline (current) alcohol intake in grams per day was obtained from intake for the age period encompassing baseline. Beverage-specific total intakes within age periods were summed to obtain total lifetime intakes in grams. The average lifetime alcohol intake in grams per day was derived by dividing the total lifetime intake by the total number of days within the age intervals up to baseline attendance.
What's new?
Drinking alcohol boosts colorectal cancer risk, but cancer is a heterogeneous disease. Which types, specifically, does alcohol promote? These authors collected data from more than 40,000 people, asking how much alcohol they consumed over their lifetime and comparing that with cancer risk. They found the more alcohol they drank, the higher the risk of colorectal cancer, specifically BRAF2 tumors. Drinking did not affect incidence of BRAF1 tumors. The presence or absence of a KRAS mutation didn't appear to make a difference.
Cohort follow-up and ascertainment of cases and deaths
Cases and vital status were ascertained through the Victorian Cancer Registry (VCR), the Victorian Registry of Births, Deaths and Marriages, the National Death Index and the Australian Cancer Database. Incident cases were men and women with a first histopathological diagnosis of adenocarcinoma of the colon or rectum during follow-up to December 31, 2008. Cancer incidence data was coded following the 3rd Revision of the International Classification of Diseases for Oncology (ICD-O-3): colon (C18.0, C18.2-18.9) and rectum (C19.9, C20.9). Carcinomas of the appendix, and anus and anal canal including overlapping lesions of rectum, anus and anal canal, were not included but censored at diagnosis. Insitu lesions diagnosed during follow-up were ignored.
Tumor molecular characterization and subtype classification
Archival tumor tissue was sought for all tumors diagnosed in Victoria. Diagnosis was verified and pathology was reviewed by a gastrointestinal histopathologist (CR). Tumor DNA was tested for the V600E BRAF mutation, which accounts for approximately 90% of BRAF mutations in colorectal cancer, 22 using a fluorescent allele-specific PCR discrimination method as previously described. 23 Exon 1 of KRAS was analyzed by direct Sanger sequencing. 24 Three tumor molecular subtypes were defined as follows: BRAF1, KRAS1 and BRAF2/ KRAS2 (BRAF1/KRAS1 does not occur frequently). Wald tests from Cox regression models were used to assess linear trends for a 10 g/day increment in alcohol intake and for intake categories as a continuous measure. To test for heterogeneity in the HRs across molecular and anatomic subtypes of colorectal cancer, Cox regression models were fitted using a competing risks method. 26 Dose-response relationships between lifetime alcohol intake (as a continuous variable) and colorectal cancer incidence were examined by comparing models that included alcohol as a linear term only and as restricted cubic splines (four knots). 27 We fitted interaction terms to test for differences in associations by attained 
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age (by splitting the data by median age at diagnosis). Subgroup analyses by gender were performed. A causal diagram (directed acyclic graph) and existing evidence were used to determine confounding variables to be included in the multivariable-adjusted models. These were sex, education (primary school, some high/technical school, completed high/technical school, completed tertiary degree/ diploma), socioeconomic status (quintiles ranging from most to least disadvantaged), smoking (never, former, current), physical activity (none, low, moderate, high), total red meat intake (quartiles), energy from food not including alcoholic beverages (continuous), dietary fiber intake (continuous) and dietary folate intake (continuous), and all models were stratified by country of birth (Australia/New Zealand, United Kingdom, Italy, Greece). Because waist circumference might be a consequence rather than a cause of alcohol consumption, we fitted models with (continuous) and without adjustment for this variable. We considered the model without adjustment for waist circumference to be the primary analysis.
In the subtype analysis, cases missing tumor molecular data were censored at diagnosis. In a sensitivity analysis, all participants diagnosed with any cancer other than colorectal cancer were censored at diagnosis. In addition, associations for baseline ("current") alcohol intake were also assessed. Each model was examined for outliers and influential points. 28 Nested models were compared using the likelihood ratio test. 29 Tests based on Schoenfeld residuals showed no evidence that proportional hazard assumptions were violated. 30 All statistical tests were two-sided, and P-values <0.05 were considered statistically significant. All statistical analyses were performed using Stata 14.1 (StataCorp, College Station, TX).
Results
Characteristics of all 38,149 participants and cases by molecular and anatomic subtype are given in Table 1 . The study had more females (59.5%) than males, and the majority were born in Australia, New Zealand or the UK (76.1%) ( Table 1 ). More than half had never smoked and only 11% were current smokers. Almost a third of the participants did not consume alcohol and about half the participants consumed <20 g/day (Table1). Of those who consumed alcohol, men reported median intakes of 17.6, 6.4 and 4.5 g/day for total alcohol, beer and wine respectively (very few drank spirits), while women reported a median alcohol intake of 6.3 g/day.
By the end of follow-up (average 14.6 years/person), 922 incident cases of colorectal cancer were diagnosed (596, 64.6% colon; 326, 35.4% rectum), 1,428 participants had left Victoria and 4,153 had died. Molecular pathology data were obtained for 670 (73%) of the tumors; Figure 1 shows the reasons why data on BRAF/KRAS status were not obtained. The participants missing BRAF/KRAS status were not different in terms of their baseline characteristics from those with this information (Supporting Information Table 1 ).
There were 111 colorectal cancers (16.6%) that had BRAF mutations, 183 (27.3%) that had KRAS mutations and 376 (56.1%) that were BRAF2/KRAS2. Of all tumors with molecular data, 423 (63.1%) were located in the colon, including 85.6% of the BRAF1 tumors, 63.4% of the KRAS1 tumors and 56.4% of the BRAF2/KRAS2 tumors. Nearly two-thirds of the patients with BRAF1 tumors were female while there were more males than females that had the other two subtypes (Table 1) . BRAF1 tumors were rare for participants born in Italy or Greece (Table 1) . Compared with patients whose tumors were KRAS1 or BRAF2/KRAS2, a higher proportion of patients with BRAF1 tumors were lifetime abstainers from alcohol and fewer consumed 30 g/day (Table 1) .
Lifetime alcohol intake and colorectal cancer risk
These analyses included all 922 cases of colorectal cancer. Lifetime alcohol consumption was associated with an increased incidence of colorectal cancer (HR 5 1.08, 95% CI: 1.04-1.12 for a 10 g/day increment, p for trend 5<0.001; HR 5 1.50, 95% CI: 1.15-1.95 for a lifetime intake of 40 g/ day compared with lifetime abstention; p for trend 5 0.001) ( Table 2 ). The model with the cubic splines fitted no better than a model with a single linear term for lifetime intake (p 5 0.5). This association was significant for males (HR 5 1.06, 95% CI: 1.02-1.11 for a 10 g/day increment, p for trend 5 0.003) and females (HR 5 1.10, 95% CI: 1.00-1.21 for a 10 g/day increment, p for trend 5 0.05) ( Table 2) . For males, a HR of 1.08 (95% CI: 1.03-1.14, p for trend 5 0.004) for colorectal cancer was observed for a 10 g/ day increment in beer intake while the evidence for an association for wine was weaker (HR 5 1.07, 95% CI: 0.99-1.17 for a 10 g/day increment, p for trend 5 0.09); too few women drank beer to undertake a similar comparison. Associations did not change materially when waist circumference was included in the models (Supporting Information Table 2 ).
Associations with molecular subtypes of colorectal cancer
Lifetime alcohol intake was associated with increased incidence of KRAS1 and BRAF2/KRAS2 tumors (HR 5 1.07, 95% CI: 1.00-1.15 and HR 5 1.05, 95% CI: 1.00-1.11 respectively, for a 10 g/day increment) but not BRAF1 tumors (HR 5 0.89, 95% CI: 0.78-1.01 for a 10 g/day increment) (p homogeneity 5 0.01) ( Table 3 ). Using BRAF status alone, a higher incidence of BRAF2 (HR 5 1.06, 95% CI: 1.01-1.11 for a 10 g/day increment) and a lower incidence of BRAF1 tumors (HR 5 0.89, 95% CI: 0.78-1.01 for a 10 g/day increment) associated with lifetime alcohol intake was observed (p homogeneity 5 0.003) ( Table 3 ). The associations between lifetime alcohol intake and the two KRAS molecular subtypes did not differ (p homogeneity 5 0.3) ( Table 3) .
Site-specific associations (colon versus rectum)
An increment in lifetime alcohol intake by 10 g/day was associated with a greater incidence of rectal cancer Table 3 ). There was no evidence of interactions with attained age for colon (p 5 0.6) or rectal cancer (p 5 0.09) when the data were split according to median age at diagnosis (70 and >70 years).
Sensitivity analysis
HRs for overall colorectal cancer or molecular and anatomic subtypes did not change when individuals diagnosed with any cancer (apart from colorectal cancer) were censored at diagnosis (results not shown). In addition, current alcohol intake at baseline was also associated with an increased incidence of colorectal cancer (HR 5 1.05, 95% CI: 1.01-1.09 for a 10 g/day increment, p for trend 5 0.02) but a difference in association between BRAF1, KRAS1 and BRAF2/KRAS2 subtypes was not observed (p homogeneity 5 0.2).
Discussion
Our results confirm an association between lifetime alcohol intake and risk of colorectal cancer. A greater risk was observed for rectal than for colon cancer in this analysis. Alcohol intake was positively related to risk of BRAF2 tumors irrespective of their KRAS status but not to risk of BRAF1 tumors. For BRAF2 tumors, alcohol intake was positively associated with both colon and rectal tumors, but the association was weaker and not significant for colon cancer. One of the main strengths of the present study is the availability of alcohol consumption data from age 20 especially considering that carcinogenesis is a chronic process. Also, abstainers for current intake might be contaminated by quitters. Other strengths include the relatively large number of colorectal cancers for which tumor BRAF and KRAS status were assessed according to standardized protocols, the prospective nature of the study, the near complete follow-up of cases through the population cancer registry, the low rates of attrition, and the availability of a range of demographic, clinical and lifestyle data. Nevertheless, several limitations exist: measurement error due to respondents having to summarize their frequency and quantity of alcoholic beverage intake for 10-year age intervals into single "usual" values, potential for present intake to influence recall of past intake and underreporting of past intake, residual confounding by unmeasured factors, and the fact that alcohol intake could have changed after the baseline assessment. We were unable to obtain archival tissue from the primary lesion to establish BRAF/ KRAS status for about one quarter of the cases. However, this is unlikely to have biased the observed associations because the proportions of cases with and without BRAF/KRAS status varied little by ethnicity or sex, which were both strongly associated with molecular subtype. 31 Also, the possible lower sensitivity of the technique employed to detect KRAS mutation may have contributed to an absence of a difference in association between KRAS1 and BRAF2/KRAS2 tumors.
In a recent meta-analysis, we found a relative risk of 1.49 for colorectal cancer associated with long term alcohol intake comparing the highest with the lowest intake category. 2 The excess risk associated with heavy drinking in this study for all colorectal cancer is similar. Biological mechanisms proposed for alcohol-associated colorectal carcinogenesis include effects on carcinogen metabolism and hormone levels, 32 direct cellular injury and gene mutations in the large intestine caused by acetaldehyde, 33 decreased glutathione levels and the elimination of free radicals, 34 increased cell proliferation in the rectal mucosa 17 and aldehyde dehydrogenase and alcohol dehydrogenase genetic status which is thought to modify the association between alcohol and colorectal cancer. 35 The plausible relationship between alcohol intake and altered onecarbon metabolism that could result in aberrations in DNA methylation with or without epigenetic modifications has been the focus of recent investigations. 36, 37 BRAF and KRAS are oncogenes that affect intracellular signaling pathways and are associated with global molecular characteristics which cause alterations of gene function on a genome-wide scale. For example, BRAF1 is associated with high degree of CIMP [38] [39] [40] and KRAS1 with CIMP-low. 39, 41, 42 CIMP is characterized by a propensity for widespread CpG island hypermethylation 43 and is important for defining a specific etiologic pathway of tumorigenesis among colorectal cancers under certain conditions. 44 BRAF and KRAS, on the other hand, are now part of routine clinical assessments for screening for Lynch syndrome and for assessing response to anti-EGFR therapy, respectively, rather than assessment of CIMP. 45, 46 Colorectal cancers can be divided into two broad subgroups: CIMP-high/BRAF1/KRAS2 and CIMP-low or CIMP2/BRAF2/KRAS1 or -tumors. 3, 4 Substantial evidence exists to suggest that CIMP-high (hence BRAF1) colorectal tumors arise through the "serrated" pathway rather than the "traditional" adenoma-carcinoma pathway. 44, [47] [48] [49] [50] [51] A previous analysis using MCCS data had confirmed an association between BRAF1 and CIMP1 tumors, and an underlying genetic basis for differential etiologies of colorectal cancer. 31 The association of lifetime alcohol intake with an increased risk of BRAF2 tumors in the present study suggests that the effects of alcohol on colorectal cancer development are restricted to tumors that arise through the traditional adenoma-carcinoma pathway of tumorigenesis. This pathway results in the development of tumors that are predominantly microsatellite stable (MSS), CIMP2 and frequently harbor KRAS mutations, although the Lynch syndrome subtype of tumors demonstrating high levels of MSI are also thought to develop via adenoma-carcinoma pathway. 4 Our evidence does not suggest that the risk differs for the adenomacarcinoma pathway according to the presence or otherwise of a KRAS mutation. In contrast, we observed no positive association between lifetime alcohol intake and colorectal cancers that harbored the BRAF V600E somatic mutation, a hallmark of tumor development through the "serrated" pathway. Previously, the Nurses' Health Study has reported HRs of 1.36 (95% CI: 0.67-2.74) for BRAF2 and 1.05 (95% CI: 0.71-1.56) for BRAF1 colon cancer associated with an alcohol intake of 15 g/day for women. 15 Similar findings were reported for participants in the Iowa Women's Health Study:
HRs of 1.19 (95% CI: 0.91-1.57) for BRAF2 and 0.95 (95% CI: 0.61-1.46) for BRAF1 colorectal cancer associated with an intake of >3.4 g/day. 16 Neither study observed a dosedependent association between alcohol intake and overall colon 15 or colorectal cancer risk. 16 Further, a recent casecontrol study reported odds ratios of 1.30 (95% CI: 0.91-1.85) for adenomas and 0.99 (95% CI: 0.68-1.47) for serrated polyps associated with an alcohol intake of 14 drinks/ week. 52 While published studies which predominantly used current intake have not established a clear difference in risk for the associations of colon and rectal cancer with alcohol, 53 the European Prospective Investigation into Cancer and Nutrition reported HRs of 1.12 (95% CI: 1.06-1.18) for rectal and 1.05 (95% CI: 1.00-1.11) for colon cancer for a 15 g/day increment in lifetime alcohol intake but did not report a formal test result comparing HRs. 54 We have shown a greater risk of rectal than colon cancer associated with alcohol in line with the explanation for greater exposure of distal colorectal mucosa to the carcinogenic effects of acetaldehyde than the proximal part. 17 We are unable to confirm whether there is a definitive site-specific difference in risks and found little evidence suggestive of a site-specific difference in risks for BRAF2 tumors. Further epidemiologic evidence is needed to confirm a gradient of increasing associations from proximal to the distal colorectum for alcohol intake along with further mechanistic explanations for this putative relationship.
In summary, we have confirmed that the association between alcohol intake and the risk of colorectal cancer might be limited to specific molecular pathways including the "traditional" adenoma-carcinoma pathway, the etiologic pathway for the majority of colorectal cancer. 44 Therefore, limiting alcohol intake from a young age might help prevent occurrence of a sizeable proportion of colorectal cancer.
